• Seunghyun Lewis Kwon, Minju Song, Wonkyung Lee, Jeeyeon Shin, Su-Yeon Lee, Sang-Gu Yeo, Minjeong Kim, Sanggyun Jeong, Joonku Park, Dongwoo Lee, and Sookyoung Lim.
• Division of Immunization, Korea Disease Control and Prevention Agency, Cheongju, Korea.
• J. Korean Med. Sci. 2024 Aug 19; 39 (32): e235e235.

AbstractOn May 1, 2024, the Republic of Korea lifted the infectious disease crisis alert for mpox, almost two years after the first case was reported. The Korea Disease Control and Prevention Agency (KDCA) has led the response, which included diagnosis, epidemiological investigations, treatment, and vaccination. This article particularly reviews the vaccination strategy implemented and proposes suggestions for enhancing future response efforts. Initially, the KDCA recommended pre-exposure prophylaxis for high-risk groups, later expanding to include broader demographics as domestic cases rose. By April 2024, a total of 6,863 individuals had received their first vaccine dose, with 3,875 completing the second dose of third-generation vaccines. Strategies to improve future responses include addressing stigma, securing nationally representative safety data, and conducting vaccine cost-benefit analyses. These measures will help ensure a robust and effective response to future outbreaks.© 2024 The Korean Academy of Medical Sciences.

10 keywords...

hide…